DCTH stock forecast, quote, news & analysis
Delcath Systems Inc is an oncology company... Show more
Why Delcath Systems (DCTH) Stock Is Up +26% in the Last 30 Days
Key Takeaways
- Delcath Systems (DCTH) shares rose approximately +26% over the last 30 days, climbing from about $15.36 to roughly $19.41.
- The advance was driven by a stronger-than-expected third-quarter 2026 report, reflecting accelerating HEPZATO KIT adoption and better revenue performance than consensus anticipated.
- Over the last quarter, the stock gained roughly 16%, extending a broader multi-month uptrend supported by clinical and commercial progress.
- Favorable clinical data, including CHOPIN trial results and presentations at the ESMO Congress 2026, reinforced investor confidence in the company's liver-directed therapy platform.
- Analyst sentiment remains constructive, with a consensus "Strong Buy" rating and published price targets ranging from roughly $21 to $32.
- For additional detail on Delcath's Price Targets, Earnings, and Forecast, explore the dedicated analysis pages.
- Discover curated, top-performing strategies on Trending AI Robots.
Delcath Systems (DCTH) Company Overview and Market Position
Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic cancers of the liver. Its lead product, HEPZATO KIT, is a melphalan-for-injection/hepatic delivery system that administers high-dose chemotherapy directly to the liver while controlling systemic exposure. In Europe, the device component is sold as the CHEMOSAT Hepatic Delivery System for Melphalan.
The company's approved indication centers on metastatic uveal melanoma with unresectable hepatic metastases, and it is advancing clinical programs targeting additional liver-cancer indications, including colorectal and breast cancer. With a lean commercial footprint, high gross margins, and a growing network of treatment centers, Delcath is positioned as a specialized player in the liver-directed therapy niche. Investors follow the stock closely for updates on HEPZATO KIT utilization, treatment-center expansion, and pipeline readouts.
Delcath Systems (DCTH) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, DCTH advanced approximately +26%, rising from a closing level near $15.36 to roughly $19.41. Much of that gain arrived in a single session tied to the company's third-quarter 2026 results, when the stock jumped sharply higher on revenue that exceeded expectations.
The quarter told a similar, if more measured, story. Measured from mid-August levels around $16.67, the stock gained roughly 16%. During that stretch, shares traded largely in a range before the recent earnings-driven breakout, reflecting a market that had been waiting for clearer confirmation of sustained commercial momentum.
What Drove DCTH Stock Price in the Last 30 Days
The primary catalyst was Delcath's third-quarter 2026 earnings report, which delivered revenue ahead of consensus expectations. Management attributed the outperformance to several factors: combination and sequencing therapy with HEPZATO KIT becoming increasingly common, patients remaining on therapy longer, and rising physician and patient awareness of the treatment. This suggests the commercial ramp is broadening rather than relying on a single driver.
Clinical visibility also supported sentiment. Data from the investigator-initiated CHOPIN randomized Phase 2 trial and presentations at the ESMO Congress 2026 reinforced the case for the company's approach, while ongoing expansion of the treatment-center network and a trained commercial team underpinned the growth narrative. These developments, combined with constructive analyst commentary, helped sustain the stock's upward move.
What Drove DCTH Stock Performance Over the Last Quarter
The broader quarterly trend was shaped by steady operational execution and an improving growth outlook. In the second quarter, Delcath reported HEPZATO KIT revenue of $27.2 million, up 21% year over year, and total revenue of $29.1 million, while raising full-year 2026 revenue guidance to a range of $104 million to $108 million. The company also reported a 90% gross margin and positive net income for the period.
At the same time, the stock contended with 340B pricing dynamics that pressured average selling prices and with seasonality in patient scheduling. Those headwinds kept shares range-bound through much of the quarter. The third-quarter beat then provided the confirmation investors had been waiting for, converting cautious optimism into a sharp repricing of the stock.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a platform offering hundreds of automated strategies that trade thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving users a focused view of strategies that are currently gaining traction. These bots vary in approach, trading timeframe, and performance metrics, so investors can review different styles before exploring further. The page serves as a practical starting point for anyone interested in data-driven, automated trading ideas across the market.
DCTH Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to monitor several factors. The most immediate is the company's guidance commentary and any update on HEPZATO KIT utilization trends, treatment-center additions, and new patient starts. Progress on pipeline indications for metastatic colorectal cancer and HER2-negative metastatic breast cancer could meaningfully expand the addressable market over time.
Other variables to watch include 340B pricing effects on realized pricing, gross-margin stability, clinical trial enrollment and data milestones, and broader market sentiment toward small-cap healthcare and medical-device names. As with any clinical-stage commercial story, execution consistency and the pace of commercial adoption will be key signals for the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DCTH in upward trend: 10-day moving average broke above 50-day moving average on November 10, 2026
The 10-day moving average for DCTH crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on DCTH as a result. In 73 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for DCTH just turned positive on November 04, 2026. Looking at past instances where DCTH's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
DCTH moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +39.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCTH advanced for three days, in 198 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
DCTH broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DCTH entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. DCTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.276) is normal, around the industry mean (4.142). DCTH's P/E Ratio (1493.000) is considerably higher than the industry average of (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.757) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices